Literature DB >> 22483615

Galactosemia: when is it a newborn screening emergency?

Gerard T Berry1.   

Abstract

Classic galactosemia is an autosomal recessive disorder of carbohydrate metabolism, due to a severe deficiency of the enzyme, galactose-1-phosphate uridyltransferase (GALT), that catalyzes the conversion of galactose-1-phosphate and uridine diphosphate glucose (UDPglucose) to uridine diphosphate galactose (UDPgalactose) and glucose-1-phosphate. Upon consumption of lactose in the neonatal period, the affected infants develop a potentially lethal disease process with multiorgan involvement. Since the advent of newborn screening (NBS) for galactosemia, we rarely encounter such overwhelmingly ill newborns. After ascertainment that the positive NBS indicates the possibility of galactosemia due to GALT deficiency, the critical question for the physician is whether the infant has the classic or a variant form of GALT deficiency, as classic galactosemia is a medical emergency. However, there are over 230 GALT gene mutations that have been detected around the world. Yet, most positive NBS tests are due to the Duarte biochemical variant condition or a simple false positive. In order to make the correct decision as well as provide informative counseling to parents of infants with a positive NBS, I utilize a relatively simple classification scheme for GALT deficiency. There are three basic forms of GALT deficiency: 1) classic galactosemia; 2) clinical variant galactosemia; and 3) biochemical variant galactosemia. The classic genotype is typified by Q188R/Q188R, the clinical variant by S135L/S135L and the biochemical variant by N314D/Q188R. In classic galactosemia, the erythrocyte GALT enzyme activity is absent or markedly reduced, the blood galactose and erythrocyte galactose-1-phosphate levels are markedly elevated, and the patient is at risk to develop potentially lethal E. coli sepsis, as well as the long-term diet-independent complications of galactosemia. Patients with the clinical variant form require treatment but do not die from E. coli sepsis in the neonatal period. If the clinician suspects galactosemia, even if based on clinical findings alone, then the infant should be immediately placed on a lactose-restricted diet. The purpose of this review is to help the clinician make the correct therapeutic decision after an NBS test has returned positive for galactosemia.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22483615     DOI: 10.1016/j.ymgme.2012.03.007

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  15 in total

1.  Newborn screening for galactosemia: a 30-year single center experience.

Authors:  Francesco Porta; Severo Pagliardini; Veronica Pagliardini; Alberto Ponzone; Marco Spada
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

Review 2.  Nutritional Genomics and Direct-to-Consumer Genetic Testing: An Overview.

Authors:  Marta Guasch-Ferré; Hassan S Dashti; Jordi Merino
Journal:  Adv Nutr       Date:  2018-03-01       Impact factor: 8.701

3.  Genetic and functional studies reveal a novel noncoding variant in GALT associated with a false positive newborn screening result for galactosemia.

Authors:  Ying Liu; Alpa Sidhu; Lora H Bean; Robert L Conway; Judith L Fridovich-Keil
Journal:  Clin Chim Acta       Date:  2015-04-25       Impact factor: 3.786

4.  Motor and speech disorders in classic galactosemia.

Authors:  Nancy L Potter; Yves Nievergelt; Lawrence D Shriberg
Journal:  JIMD Rep       Date:  2013-04-02

5.  Newborn screening for galactosemia in the United States: looking back, looking around, and looking ahead.

Authors:  Brook M Pyhtila; Kelly A Shaw; Samantha E Neumann; Judith L Fridovich-Keil
Journal:  JIMD Rep       Date:  2014-04-10

6.  Clinical, molecular, and genetic evaluation of galactosemia in Turkish children.

Authors:  Sezen Ugan Atik; Semra Gürsoy; Tuba Koçkar; Hasan Önal; Servet Erdal Adal
Journal:  Turk Pediatri Ars       Date:  2016-12-01

Review 7.  Drosophila melanogaster Models of Galactosemia.

Authors:  J M I Daenzer; J L Fridovich-Keil
Journal:  Curr Top Dev Biol       Date:  2016-08-03       Impact factor: 4.897

8.  Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors.

Authors:  Li Liu; Manshu Tang; Rajan Pragani; Frank G Whitby; Ya-Qin Zhang; Bijina Balakrishnan; Yuhong Fang; Surendra Karavadhi; Dingyin Tao; Christopher A LeClair; Matthew D Hall; Juan J Marugan; Matthew Boxer; Min Shen; Christopher P Hill; Kent Lai; Samarjit Patnaik
Journal:  J Med Chem       Date:  2021-09-07       Impact factor: 7.446

9.  Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

Authors:  Yue Tang; Yuanyuan Kong
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

10.  The genetic basis of classical galactosaemia in Polish patients.

Authors:  Aleksandra Jezela-Stanek; Anna Bauer; Katarzyna Wertheim-Tysarowska; Jerzy Bal; Agnieszka Magdalena Rygiel; Jolanta Sykut-Cegielska
Journal:  Orphanet J Rare Dis       Date:  2021-05-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.